Mycophenolate Mofetil IR Pellets are pharmaceutical-grade immediate-release multiparticulate pellets containing Mycophenolate Mofetil as the active pharmaceutical ingredient. They are designed for oral formulation applications where rapid release of the active ingredient from individual pellet units is required.
Mycophenolate Mofetil is identified by CAS Number 128794-94-5, molecular formula C₂₃H₃₁NO₇, and molecular weight 433.5 g/mol. The molecule is the morpholinoethyl ester of mycophenolic acid and is an important pharmaceutical active ingredient used in formulations requiring controlled and consistent active-ingredient delivery.
Commercial pharmaceutical pellet references document Mycophenolate Mofetil IR Pellets at 90% w/w, while another commercial pellet portfolio documents a 50% w/w format. This demonstrates that different active-loading levels exist commercially; therefore, the strength displayed on the SDP website should correspond specifically to the applicable SDP product specification or COA.
The immediate-release pellet format provides a multiparticulate platform in which active loading, pellet size, physical characteristics, active distribution and dissolution performance can be controlled according to the intended oral formulation.
Mycophenolate Mofetil Immediate-Release Pellets are developed as multiple individual pellet units rather than a single-unit formulation. This multiparticulate structure provides flexibility during pharmaceutical formulation development and downstream processing.
The performance of an immediate-release pellet system can be influenced by the pellet core composition, active loading, particle-size distribution, porosity, surface characteristics, excipient selection and manufacturing process.
For Mycophenolate Mofetil formulations, maintaining consistent active distribution is particularly important because the active ingredient must be uniformly incorporated throughout the pellet population. Appropriate control of pellet composition and manufacturing parameters can support consistent finished-product characteristics.
Commercial references demonstrate different Mycophenolate Mofetil pellet loading levels, including 90% w/w and 50% w/w formats.
For the SDP website, the available strength should be taken directly from the current SDP specification rather than assuming a commercial reference strength.
Available Strength: Product-specific / confirm current SDP specification
Active loading is an important characteristic of Mycophenolate Mofetil IR Pellets because it determines the amount of active ingredient present in a defined pellet mass. Loading can also influence the ratio of active ingredient to excipients, pellet structure, manufacturing characteristics and downstream capsule-filling requirements.
The multiparticulate structure of Mycophenolate Mofetil IR Pellets provides flexibility for oral formulation development. Each pellet functions as an individual unit, while the complete formulation contains a controlled population of pellets with defined physical and chemical characteristics.
Mycophenolate Mofetil IR Pellets can be considered for:
The final suitability of the pellets depends on the intended formulation, manufacturing process and applicable finished-product specification.
Capsule filling is an important application of pharmaceutical multiparticulate pellets. Mycophenolate Mofetil IR Pellets can be developed with suitable particle-size distribution, density and mechanical characteristics to support capsule-filling operations.
Consistent pellet characteristics can help support reproducible filling and uniform active distribution. Important physical characteristics may include particle size, bulk density, tapped density, friability, sphericity, moisture content and pellet morphology.
The appropriate physical specifications should be established according to the intended formulation and finished-product requirements.
The release performance of Mycophenolate Mofetil IR Pellets depends on formulation and manufacturing design. Important variables can include:
An immediate-release pellet system should be evaluated using an appropriate validated dissolution method. The exact dissolution acceptance criteria are product-specific and should be established according to the applicable finished-product specification.
Active loading is a key quality attribute for Mycophenolate Mofetil IR Pellets. The intended concentration of Mycophenolate Mofetil should remain consistent throughout the manufactured batch.
Content uniformity is particularly important for multiparticulate formulations because consistent active distribution helps support reproducible finished-product performance. Appropriate process controls and validated analytical testing can be used to evaluate active distribution and batch consistency.
The active ingredient's chemical specification should also be clearly distinguished from the finished-pellet specification. A finished pellet containing a defined percentage of Mycophenolate Mofetil requires its own assay and acceptance criteria based on the specified active loading.
High-quality Mycophenolate Mofetil Pharmaceutical Pellets can be evaluated through chemical, physical and performance-related characteristics.
Chemical evaluation may include:
Physical evaluation may include:
Performance evaluation may include:
The final acceptance criteria should be based on the applicable finished-product specification.
Mycophenolate Mofetil IR Pellets provide a flexible multiparticulate platform for immediate-release formulation development. Formulation developers can evaluate active loading, pellet size, core composition and physical characteristics according to the intended formulation.
The pellet format can also support process optimization and scale-up by providing defined physical characteristics for downstream manufacturing operations.
During formulation development, parameters such as active loading, pellet size, excipient composition and manufacturing conditions can be evaluated to achieve consistent finished-product characteristics.
For pharmaceutical manufacturers developing oral multiparticulate formulations, consistent pellet characteristics can support reproducible processing, capsule filling and finished-product quality.
Mycophenolate Mofetil IR Pellets from Swapnroop are positioned as pharmaceutical-grade multiparticulate pellets for immediate-release formulation and bulk pharmaceutical applications.
Key product advantages include:
As a Mycophenolate Mofetil IR Pellets Manufacturer and Supplier in India, Swapnroop can position Mycophenolate Mofetil immediate-release pellets for pharmaceutical formulation development, multiparticulate applications, capsule filling and bulk pharmaceutical requirements.
Commercial pellet references demonstrate both high-loading and lower-loading formats, so the final active loading should always be aligned with the applicable SDP product specification rather than copied from another manufacturer's product.
Customers searching for Mycophenolate Mofetil IR Pellets Manufacturer in India, Mycophenolate Mofetil IR Pellets Supplier in India, Mycophenolate Mofetil Pharmaceutical Pellets, Mycophenolate Mofetil Immediate-Release Pellets, Mycophenolate Mofetil Multiparticulate Pellets, and Mycophenolate Mofetil Pellets for Capsule Filling can be naturally addressed through the product page's topical content.
Mycophenolate Mofetil IR Pellets can be supplied in suitable pharmaceutical packaging according to the required:
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 1.0% |